Original InvestigationInhaled Xenon Attenuates Myocardial Damage in Comatose Survivors of Out-of-Hospital Cardiac Arrest: The Xe-Hypotheca Trial
Central Illustration
Key Words
Abbreviations and Acronyms
Cited by (0)
The study was funded by the Academy of Finland and by clinical research funding from the Hospital District of Southwest Finland. The study was academic, that is, the funding organizations did not have any role in design and conduct of the study, collection, management, analysis, and interpretation of the data and preparation, review, or approval of the manuscript. Dr. R. Laitio is a paid governmental consultant official for the National Supervisory Authority for Welfare and Health. Dr. Maze is a founder, board director, and equity shareholder of NeuroproteXeon, a company that intends to commercialize the use of xenon for ongoing acute neurological injury, including its administration to successfully resuscitated patients after out-of-hospital cardiac arrest. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.